Has Paarth Shah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $298,899 in general payments to Paarth Shah, MD across 2,000 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paarth Shah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paarth Shah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paarth Shah, MD

Neurology · Gilbert, AZNPI 1356695894

Payments from drug & device makers

$298,899in general payments, 2019–2025

Across 2,000 payments — averaging $149.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Acorda Therapeutics, Inc$87K
AbbVie$71K
MDD US Operations, LLC$59K
Neurocrine Biosciences, Inc.$33K
Amneal Pharmaceuticals LLC$10K
Medtronic$10K
plus $28K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Acorda Therapeutics, Inc	162	$87,239
AbbVie(2 entities)	484	$71,004
MDD US Operations, LLC	164	$59,168
Neurocrine Biosciences, Inc.	75	$32,565
Amneal Pharmaceuticals LLC	60	$10,294
Medtronic(2 entities)	154	$9,985
GRT US Holding, Inc.	11	$4,812
Otsuka America Pharmaceutical, Inc.	21	$4,309
Sunovion Pharmaceuticals Inc.	6	$2,115
Abbott	55	$2,085
Amgen(2 entities)	75	$1,999
Boston Scientific	34	$1,286
UCB, Inc.	78	$1,047
AstraZeneca(2 entities)	22	$705
Argenx US, Inc.	39	$696
Avanir Pharmaceuticals, Inc.	40	$689
Eisai Inc.	29	$575
Acadia Pharmaceuticals Inc	32	$565
Upsher-smith Laboratories LLC	36	$462
Novartis	27	$459
Teva Pharmaceuticals USA, Inc.	29	$456
Lilly USA, LLC	29	$456
Lundbeck LLC	16	$385
Genentech USA, Inc.	14	$347
Biohaven Pharmaceutical Holding Company Ltd.	37	$343
Pfizer	35	$337
SK Life Science, Inc.	10	$311
Biogen	14	$292
CSL Behring	10	$276
Banner Life Sciences, LLC	24	$249
Kyowa Kirin, Inc.	13	$245
Mallinckrodt Hospital Products Inc.	9	$231
Sanofi	6	$231
Avion Pharmaceuticals	11	$191
Supernus Pharmaceuticals, Inc.	4	$171
Merz North America, Inc.	7	$160
Johnson & Johnson	13	$142
Biohaven Pharmaceuticals, Inc.	18	$136
Bristol Myers Squibb	6	$124
Impel Pharmaceuticals Inc.	5	$119
GE HealthCare	6	$116
Merz Pharmaceuticals, LLC	5	$109
Adamas Pharmaceuticals, Inc.	6	$96
Vanda Pharmaceuticals Inc.	3	$95
Takeda Pharmaceuticals U.S.A., Inc.	4	$90
Ipsen Biopharmaceuticals, Inc	5	$83
Cala Health, Inc.	2	$74
Jazz Pharmaceuticals Inc.	4	$73
EMD Serono, Inc.	3	$67
Vertical Pharmaceuticals, LLC	3	$57
Cycle Pharmaceuticals Inc	2	$53
Neurelis, Inc.	3	$52
Insightec,inc	2	$50
Currax Pharmaceuticals LLC	3	$43
Livanova USA, Inc.	3	$43
Impel Pharmaceuticals LLC	2	$42
Grifols USA, LLC	2	$40
Nalu Medical, Inc.	2	$39
Bausch Health US, LLC	2	$34
Corium, LLC	2	$31

How this compares

$298,899 in reported general payments places this provider in the 85th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024

$112,598

Medicare patients

371

Services billed

8,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Gilbert

Jonathan HodgsonGilbert$1.8M
William GraingerGilbert$338K
David WeidmanPhoenix$7.4M
Hemant PandeyChandler$6.2M
Stephen FlitmanPhoenix$4.4M
Barry HendinPhoenix$4.4M
Jeremy ShefnerPhoenix$3M
Danielle CabralPhoenix$2.8M
Suraj MuleyPhoenix$2.8M
Todd SchwedtPhoenix$2.8M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →